Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.
Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, Salmenniemi U, Dreger P, von dem Borne P, Snowden JA, Robinson S, Finazzi MC, Schroeder T, Collin M, Eder M, Forcade E, Loschi M, Bramanti S, Pérez-Simón JA, Czerw T, Polverelli N, Drozd-Sokolowska J, Raj K, Hernández-Boluda JC, McLornan DP. Robin M, et al. Among authors: hernandez boluda jc. Bone Marrow Transplant. 2024 Mar 15. doi: 10.1038/s41409-024-02269-4. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38491198
Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.
Solano C, Giménez E, Albert E, Mateo EM, Gómez M, Goterris R, Pérez A, Amat P, Hernández-Boluda JC, Poch M, Piñana JL, Navarro D. Solano C, et al. Bone Marrow Transplant. 2019 Jan;54(1):90-98. doi: 10.1038/s41409-018-0251-0. Epub 2018 Jun 13. Bone Marrow Transplant. 2019. PMID: 29899574 Clinical Trial.
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I. McLornan D, et al. Biol Blood Marrow Transplant. 2019 Nov;25(11):2167-2171. doi: 10.1016/j.bbmt.2019.06.034. Epub 2019 Jul 5. Biol Blood Marrow Transplant. 2019. PMID: 31284069 Free article.
The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey.
Piñana JL, Pérez A, Montoro J, Hernani R, Lorenzo I, Giménez E, Gómez MD, Guerreiro M, González-Barberá EM, Carretero C, Salavert M, Balaguer-Roselló A, Sanz G, Hernández-Boluda JC, Solano C, Sanz J, Navarro D. Piñana JL, et al. Bone Marrow Transplant. 2020 Feb;55(2):431-440. doi: 10.1038/s41409-019-0698-7. Epub 2019 Sep 24. Bone Marrow Transplant. 2020. PMID: 31551521 Free PMC article.
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
Hernández-Boluda JC, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, Angelucci E, Vitek A, Blau IW, Niittyvuopio R, Finke J, Cornelissen JJ, Passweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. Hernández-Boluda JC, et al. Leukemia. 2021 Jan;35(1):215-224. doi: 10.1038/s41375-020-0815-z. Epub 2020 Apr 14. Leukemia. 2021. PMID: 32286544
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT).
Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, Beauvais D, Chevallier P, Mohty M, Passweg J, Rubio MT, Maertens J, Finke J, Bornhäuser M, Vrhovac R, Helbig G, Mear JB, Castagna L, Reményi P, Angelucci E, Karakasis D, Rifòn J, Sirait T, Russo D, de Wreede L, Czerw T, Hernández-Boluda JC, Hayden P, McLornan D, Yakoub-Agha I. Polverelli N, et al. Am J Hematol. 2021 Jan;96(1):69-79. doi: 10.1002/ajh.26020. Epub 2020 Oct 27. Am J Hematol. 2021. PMID: 33064301 Free article. Clinical Trial.
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Battipaglia G, Mauff K, Wendel L, Angelucci E, Mohty M, Arcese W, Santarone S, Rubio MT, Kroger N, Fox ML, Blaise D, Iori AP, Fanin R, Chalandon Y, Pioltelli P, Marotta G, Chiusolo P, Sever M, Solano C, Contentin N, de Wreede LC, Czerw T, Hernandez-Boluda JC, Hayden P, McLornan D, Yakoub-Agha I. Battipaglia G, et al. Bone Marrow Transplant. 2021 Jul;56(7):1593-1602. doi: 10.1038/s41409-021-01222-z. Epub 2021 Feb 1. Bone Marrow Transplant. 2021. PMID: 33526919
Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT.
Nabergoj M, Mauff K, Robin M, Kröger N, Angelucci E, Poiré X, Passweg J, Radujkovic A, Platzbecker U, Robinson S, Rambaldi A, Petersen SL, Stölzel F, Stelljes M, Ciceri F, Mayer J, Ladetto M, de Wreede LC, Koster L, Hayden PJ, Czerw T, Hernández-Boluda JC, McLornan D, Chalandon Y, Yakoub-Agha I. Nabergoj M, et al. Bone Marrow Transplant. 2021 Aug;56(8):1944-1952. doi: 10.1038/s41409-021-01271-4. Epub 2021 Apr 6. Bone Marrow Transplant. 2021. PMID: 33824436
224 results